Successful clinical response to immune checkpoint blockade has been linked with multiple features, such as IFNγ signatures, PD-1/PD-L1 expression, size and quantity of tumor-associated tertiary lymphoid organs, presence of B cells, and memory T cell phenotypes (59, 63–65). Here, PDCD1 is linked to neoplasm.